AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

I was reading the new $ATAI update about their EMP-01 program for social anxiety and honestly it was interesting to see an early patient study actually finish cleanly. They enrolled 71 adults in the UK and almost everyone stayed in the trial through the 43-day check in, which at least shows people were willing to continue the treatment.

The main thing they wanted to see was safety and they reported no serious problems, with most side effects described as mild. They also tracked symptom changes and the treated group improved more than placebo by about 12 points on the main anxiety score after six weeks. Doctors also rated overall improvement and 49% of patients on the treatment were considered improved compared to 15% on placebo. What caught my attention is they only gave two doses spaced a month apart and no therapy, yet they still reported less fear and less social avoidance.

I’m just trying to understand where this goes from here. If anyone here has been following $ATAI longer, what usually happens after a study like this and how long before the next trial?